Results 161 to 170 of about 1,976,966 (315)

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Additional file 3 of Is it time to RE-AIM? A systematic review of economic empowerment as HIV prevention intervention for adolescent girls and young women in sub-Saharan Africa using the RE-AIM framework

, 2020
Juliet Iwelunmor, Ucheoma Nwaozuru, Chisom Obiezu‐Umeh, Florida Uzoaru, John Ehiri, Jami Curley, Oliver Ezechi, Collins O. Airhihenbuwa, Fred M. Ssewamala   +8 more
openalex   +1 more source

Sovereign debt (re)structuring-Where do we stand? [PDF]

Argentina’s debt default in 2001 moved the international community to launch initiatives to develop procedures for the orderly restructuring of unsustainable sovereign debt.
Weber, P F.
core  

Designing an Electronic Patient Reported Outcomes Information Infrastructure Supported by the RE-AIM Implementation Framework

Advances in Cancer Education and Quality Improvement
ABSTRACTObjectivePatient-reported outcomes (PROs) contain valuable information that can be leveraged by providers to perform timely interventions and improve quality of life and survival. However, the implementation of electronic PROs (ePROs) remains a challenge from technical, behavioral, and evaluation perspectives.
Amy C. Moreno, Angela Peek, Toshiko S. Shein, Kevin R. Shook, Sara M. Ali, Laia Humbert-Vidan, Aileen Chen, Miriam Lango, Anna Lee, Michael Spiotto, William H. Morrison, Adam S. Garden, Jack Phan, Steven J. Frank, Katherine Hutcheson, David Rosenthal, Clifton D. Fuller, G. Brandon Gunn   +17 more
openaire   +2 more sources

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

Shared-Care in Complex Malignant Hematology: An Integrative Review Using the RE-AIM Evaluation Framework

Current Oncology
Complex malignant hematology (CMH) shared-care programs have been established to support patients with access to care closer to home. This integrative review examined what is known about CMH shared-care using the RE-AIM evaluation framework.
Shannon M. Nixon, Dawn C. Maze, Monica Parry, Samantha J. Mayo   +3 more
doaj   +1 more source

A 5-year examination of CAPABLE implementation using RE-AIM and CFIR frameworks

Frontiers in Public Health
BackgroundExamining the experience of organizations implementing evidence-based programs can help future programs address barriers to effective implementation, sustainment, and scaling. CAPABLE is an evidence-based 4-to-6-month program that improves daily function of older adults and modifies their home environments in modest ways to support their goal
Deborah L. Paone, Deborah L. Paone, Jeanne W. Schuller, Matthew Lee Smith, Matthew Lee Smith, Laura N. Gitlin, Sarah L. Szanton   +6 more
openaire   +2 more sources

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Using the RE-AIM framework to evaluate the implementation of scaling-up the Friendship Bench in Zimbabwe – a quantitative observational study [PDF]

, 2022
Ruth Verhey, Charmaine Chitiyo, Sandra Mboweni, Jean Turner, Gift Murombo, Andy Healey, Dixon Chibanda, Bradley H. Wagenaar, Ricardo Araya   +8 more
openalex   +1 more source